[ad_1]
The Norwegian entrepreneurial company Optinose has a long listing period on the New York Stock Exchange.
The nasal pump company, created by the couple Per and Helena Djupesland about 18 years ago, has lost $ 182 million, or NOK 1.6 billion, in market value since the beginning of May.
The market value of the company is Wednesday at $ 285 million, or $ 2.49 billion.
However, the stock market year was better for Optinose after a sharp decline last year as well.
At the beginning of the year, the price was $ 6.2 on the Nasdaq index, while at the beginning of May it had reached $ 11 a year.
However, this level did not last long and the price came back to about six dollars after investors fell sharply.
Much lower than the first class
The Djupesland family holds about two million shares of Optinose through the investment company Ikos Invest, according to the prospectus.
They have seen high paper values in the last two months.
At most, this participation was worth about half a billion crowns while the price of last summer had reached its highest level, just over $ 28 per share.
Ultimovacs, boss of crucial millions: – We met well
Optinose went public in 2017 at a price of $ 16, but has grown and increased by 20% on the first day of trading.
Big loss
The doctor of the ears, nose and throat, Per Djupesland, left the presidency in chief of Optinose in 2009 due to a larger gain, ceded to the American Peter Miller.
Helena and her husband are still in the management of the company, which today has its head office in Pennsylvania, USA.
Optinose is still in the development phase and therefore does not have much revenue to demonstrate by the dynamism of Norwegian entrepreneurs, called Xhance, which will make the treatment more effective.
However, the losses are significant and the figures for the first quarter, presented in early May, showed a deficit of 29 million USD, or 252 million NOK for the period.
During the year, the deficit amounted to 107 million USD, or 932 million NOK, based on the current exchange rate.
Source link
